Elanco Animal Health

At a glance

Elanco Animal Health reported 2025 revenue of $4.71B, up 6.2% from $4.44B in 2024. Over 4 years since 2021 ($4.76B), that is a decline of about 0.3% a year. Revenue peaked in 2021 at $4.76B. The company posted a loss in 2021, 2022, 2023 and 2025.

In the last 12 months 8 insiders reported 11 open-market purchases ($2.6M) and 1 sale ($100K). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a purchase of $936K by Director Lawrence Erik Kurzius on Aug 21, 2026. Net, insiders were buyers of $2.5M.

Elanco Animal Health filed 8 current reports (Form 8-K) in the last 12 months, most often for results of operations (4), shareholder vote results (1), regulation fd disclosure (1) and exit or restructuring costs (1). It reported a material agreement or a completed acquisition or disposal 1 time.

1 of the 20 investors tracked here held Elanco Animal Health at the last quarter end, worth $2M combined. It is the largest weight for Bridgewater Associates (0% of its portfolio). Reduced: Bridgewater Associates.

Annual results

Fiscal year ends Dec 31

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.